---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Chemotherapy"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Chemotherapy. Topics: Chemotherapy recommendations in third-line treatment and beyond: ESMO 2026 guideline, Single-agent chemotherapy for endocrine-pretreated disease: ASCO 2021 guideline, Comparator regulatory information: capecitabine, Comparator regulatory information: eribulin, and 8 further topics. 12 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/chemotherapy"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Chemotherapy

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Chemotherapy

<a id="topic-2.2.2.1.7-1"></a>

### Chemotherapy recommendations in third-line treatment and beyond: ESMO 2026 guideline

> “At least two lines of endocrine-based therapy can be recommended before moving to non-endocrine-based therapy in endocrine-sensitive disease [V, B].”
> “Sequential single-agent ChT is recommended over combination strategies [II, A].”
> “Combination ChT is recommended when a rapid response is needed due to imminent organ failure [V, A].”
> “Capecitabine, capecitabine–bevacizumab (not EMA or FDA approved in this line), taxane or taxane–bevacizumab (not EMA or FDA approved in this line), may be considered [I, C].”
> “If capecitabine is used, dihydropyrimidine dehydrogenase testing is recommended before treatment is initiated [V, A].”
> “Rechallenge with anthracyclines or taxanes (liposomal anthracyclines or protein-bound paclitaxel, if available) can be recommended beyond third-line treatment in patients with a disease-free interval (DFI) ≥12 months [II, B].”

Source: [de Azambuja et al. (2026)](https://www.annalsofoncology.org/article/S0923-7534(26)00902-6/fulltext)

<a id="topic-2.2.2.1.7-2"></a>

### Single-agent chemotherapy for endocrine-pretreated disease: ASCO 2021 guideline

> “Patients with HR-positive human epidermal growth factor receptor 2-negative MBC for whom chemotherapy is being considered should be offered single-agent chemotherapy rather than combination chemotherapy, although combination regimens may be offered for highly symptomatic or life-threatening disease.”
> “Patients with HR-positive MBC with disease progression on an endocrine agent may be offered treatment with either endocrine therapy with or without targeted therapy or single-agent chemotherapy.”

Source: [Moy et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34324366/)

<a id="topic-2.2.2.1.7-3"></a>

### Comparator regulatory information: capecitabine

> “treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated.”
> “Test patients for genetic variants of DPYD prior to initiating XELODA unless immediate treatment is necessary.”
> “Altered coagulation parameters and/or bleeding, including death, have been reported in patients taking XELODA concomitantly with oral vitamin K antagonists, such as warfarin”

Source: [Xeloda prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/020896s052lbl.pdf)

<a id="topic-2.2.2.1.7-4"></a>

### Comparator regulatory information: eribulin

> “HALAVEN is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.”
> “Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting”
> “In Study 1, Grade 3 peripheral neuropathy occurred in 8% (40/503) of patients, and Grade 4 in 0.4% (2/503) of patients with metastatic breast cancer (MBC).”

Source: [Halaven prescribing information (2022)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/201532s023lbl.pdf)

<a id="topic-2.2.2.1.7-5"></a>

### Comparator regulatory information: paclitaxel protein-bound

> “ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.”
> “Prior therapy should have included an anthracycline unless clinically contraindicated.”

Source: [Abraxane prescribing information (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021660s047lbl.pdf)

<a id="topic-2.2.2.1.7-6"></a>

### Eribulin versus treatment of physician's choice: EMBRACE

> “762 women were randomly allocated to treatment groups (508 eribulin, 254 TPC).”
> “Overall survival was significantly improved in women assigned to eribulin (median 13·1 months, 95% CI 11·8-14·3) compared with TPC (10·6 months, 9·3-12·5; hazard ratio 0·81, 95% CI 0·66-0·99; p=0·041).”
> “Peripheral neuropathy was the most common adverse event leading to discontinuation from eribulin, occurring in 24 (5%) of 503 patients.”

Source: [Cortes et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/21376385/)

<a id="topic-2.2.2.1.7-7"></a>

### Eribulin versus capecitabine: Study 301

> “Median OS times for eribulin (n = 554) and capecitabine (n = 548) were 15.9 and 14.5 months, respectively (hazard ratio [HR], 0.88; 95% CI, 0.77 to 1.00; P = .056).”
> “Median PFS times for eribulin and capecitabine were 4.1 and 4.2 months, respectively (HR, 1.08; 95% CI, 0.93 to 1.25; P = .30).”
> “Objective response rates were 11.0% for eribulin and 11.5% for capecitabine.”

Source: [Kaufman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4463422/)

<a id="topic-2.2.2.1.7-8"></a>

### Eribulin in hormone receptor-positive disease: pooled analysis of two phase 3 trials

> “Indeed, women with HER2-negative or triple-negative disease gained a particular benefit; the effects in patients with HER2-negative but hormone-receptor-positive disease were somewhat less robust.”

Source: [Twelves et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4243003/)

<a id="topic-2.2.2.1.7-9"></a>

### Chemotherapy compared with endocrine-based therapy: network meta-analysis

> “We identified 2689 published results and 140 studies (comprising 50 029 patients) were included in the analysis.”
> “No chemotherapy or hormone therapy regimen was significantly better than palbociclib plus letrozole for progression-free survival.”
> “Moreover, no chemotherapy regimen with or without targeted therapy is significantly better than CDK4/6 inhibitors plus hormone therapies in terms of progression-free survival.”

Source: [Giuliano et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31494037/)

<a id="topic-2.2.2.1.7-10"></a>

### Single-agent chemotherapy in the control arm of a contemporary trial: TROPION-Breast01

> “The median PFS of 4.9 months in the ICC arm of TROPION-Breast01 was generally consistent with previous reports for single-agent chemotherapy.”

Source: [Bardia et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11771365/)

<a id="topic-2.2.2.1.7-11"></a>

### Chemotherapy after first-line CDK4/6 inhibitor in practice: systematic review of real-world evidence

> “The weighted average median rwPFS for chemotherapy was 6.1 months (n = 499 total patients), calculated using data from 7 studies reporting median rwPFS values ranging from 3.7 months (n = 249)”

Source: [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/)

<a id="topic-2.2.2.1.7-12"></a>

### Chemotherapy use and outcomes in second and third lines: SOLTI-1801 CDK-PREDICT

> “In the second-line setting (n = 125), real-world therapeutic strategies included endocrine monotherapy (22%; n = 27), targeted therapies (51%; n = 65), capecitabine (10%; n = 12), and other chemotherapy agents (17%; n = 21).”
> “Targeted agents were frequent in 2L (51%) and capecitabine in 3L (36%), while endocrine monotherapy yielded poorest rwPFS.”

Source: [Tolosa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12950024/)

Additional sources: [Gradishar et al. (2026)](https://jnccn.org/view/journals/jnccn/24/7/article-e260033.xml)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
